Alebund Pharmaceuticals Announces 2026 Interim Results
Alebund Pharmaceuticals, an indirect partner of DaVita via R1 Therapeutics, reported H1 2026 revenue of RMB104.2 million, a 761% increase driven primarily by RMB79.3 million in licensing revenue from the R1 collaboration. The company narrowed its net loss by 22.5% to RMB162.6 million and strengthened its balance sheet to RMB1.39 billion in cash following its recent IPO.
Key figures
- Revenue
- RMB104.2 million
- Licensing Revenue
- RMB79.3 million
- Rd expenses
- RMB141.4 million
- Cash balance
- RMB1,392.8 million
- Adjusted net loss
- RMB130.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.